Aveanna Healthcare Holdings Announces Preliminary Third Quarter Financial Results
Aveanna Healthcare (NASDAQ: AVAH) reported preliminary results for the three-month period ended September 27, 2025. Management expects revenue of $616M–$624M, up ~21.0%–22.6% year-over-year; net income of $11M–$15M, up ~125.7%–135.0% year-over-year; and Adjusted EBITDA of $77M–$81M, up ~61.0%–69.3% year-over-year.
Results are preliminary and unaudited, subject to closing procedures and potential material adjustments. The company disclosed significant non-GAAP adjustments, including $15.7M–$16.9M of fees related to debt modifications and various acquisition and integration costs.
Aveanna Healthcare (NASDAQ: AVAH) ha riportato risultati preliminari per il trimestre chiuso al 27 settembre 2025. La direzione prevede ricavi tra 616 milioni e 624 milioni di dollari, in aumento di circa 21,0%–22,6% rispetto all'anno precedente; utile netto tra 11 milioni e 15 milioni di dollari, in incremento di circa 125,7%–135,0% rispetto all'anno precedente; e EBITDA rettificato tra 77 milioni e 81 milioni di dollari, in aumento di circa 61,0%–69,3% rispetto all'anno precedente.
I risultati sono preliminari e non auditati, soggetti a procedure di chiusura e a eventuali aggiustamenti sostanziali. L'azienda ha comunicato significativi aggiustamenti non-GAAP, tra cui 15,7–16,9 milioni di dollari di oneri correlati a modifiche del debito e a costi vari di acquisizione e integrazione.
Aveanna Healthcare (NASDAQ: AVAH) presentó resultados preliminares para el trimestre terminado el 27 de septiembre de 2025. La dirección espera ingresos de 616 millones a 624 millones de dólares, un crecimiento interanual de aproximadamente 21,0%–22,6%; utilidad neta de 11 millones a 15 millones de dólares, un crecimiento interanual de aproximadamente 125,7%–135,0%; y EBITDA ajustado de 77 millones a 81 millones de dólares, un crecimiento interanual de aproximadamente 61,0%–69,3%.
Los resultados son preliminares y no auditados, sujetos a procedimientos de cierre y posibles ajustes materiales. La empresa divulgó ajustes no-GAAP significativos, incluidas comisiones de 15,7–16,9 millones de dólares relacionadas con modificaciones de la deuda y diversos costos de adquisición e integración.
Aveanna Healthcare (NASDAQ: AVAH) 는 2025년 9월 27일 종료된 3개월 기간에 대한 예비 실적을 발표했습니다. 경영진은 매출을 6억 160만 ~ 6억 240만 달러로 예상하며, 연간 비교 대비 약 21.0%–22.6%의 증가를 예상합니다; 순이익은 1,100만~1,500만 달러, 연간 대비 약 125.7%–135.0% 증가; 그리고 조정된 EBITDA는 7,700만~8,100만 달러, 연간 비교로 약 61.0%–69.3% 증가할 것으로 보입니다.
결과는 예비적이며 감사되지 않았으며, 마감 절차와 잠재적 중대한 조정에 따라 달라질 수 있습니다. 회사는 의무 계약 수정 비용 및 인수 및 통합 비용과 같은 1,570만~1,690만 달러의 비-GAAP 조정을 포함한 중대한 조정을 공시했습니다.
Aveanna Healthcare (NASDAQ: AVAH) a publié des résultats préliminaires pour la période de trois mois se terminant le 27 septembre 2025. La direction s’attend à un chiffre d’affaires de 616 M$ à 624 M$, en hausse d’environ 21,0%–22,6% sur un an; un bénéfice net de 11 M$ à 15 M$, en hausse d’environ 125,7%–135,0% sur un an; et un EBITDA ajusté de 77 M$ à 81 M$, en hausse d’environ 61,0%–69,3% sur un an.
Les résultats sont préliminaires et non audités, soumis à des procédures de clôture et à d’éventuels ajustements importants. La société a divulgué des ajustements non-GAAP importants, notamment de 15,7 M$ à 16,9 M$ de frais liés à des modifications de dette et à divers coûts d’acquisition et d’intégration.
Aveanna Healthcare (NASDAQ: AVAH) hat vorläufige Ergebnisse für den Dreimonatszeitraum bis zum 27. September 2025 gemeldet. Das Management rechnet mit Umsätzen von 616 Mio. bis 624 Mio. USD, ein Anstieg von ca. 21,0%–22,6% gegenüber dem Vorjahr; Nettoeinkommen von 11 Mio. bis 15 Mio. USD, ein Anstieg von ca. 125,7%–135,0% gegenüber dem Vorjahr; und bereinigtes EBITDA von 77 Mio. bis 81 Mio. USD, ein Anstieg von ca. 61,0%–69,3% gegenüber dem Vorjahr.
Die Ergebnisse sind vorläufig und ungeprüft, unterliegen Closing-Verfahren und möglichen wesentlichen Anpassungen. Das Unternehmen hat signifikante nicht-GAAP-Anpassungen offengelegt, darunter 15,7–16,9 Mio. USD an Gebühren im Zusammenhang mit SchuldModifikationen und verschiedenen Kosten für Akquisition und Integration.
Aveanna Healthcare (NASDAQ: AVAH) أبلغت عن نتائج ابتدائية للمدة الثلاثة أشهر المنتهية في 27 سبتمبر 2025. تتوقع الإدارة إيرادات بين 616 مليون و624 مليون دولار، بارتفاع نحو 21.0%–22.6% على أساس سنوي؛ صافي الدخل بين 11 مليون و15 مليون دولار، بارتفاع نحو 125.7%–135.0% على أساس سنوي؛ وEBITDA معدّل بين 77 مليون و81 مليون دولار، بارتفاع نحو 61.0%–69.3% على أساس سنوي.
النتائج ابتدائية وغير مدققة، وتخضع لإجراءات الإغلاق واحتمالية تعديلات جوهرية. كشفت الشركة عن تعديلات غير GAAP كبيرة، بما في ذلك بين 15.7 مليون و16.9 مليون دولار من الرسوم المتعلقة بتعديل الدين وتكاليف الاستحواذ والدمج المتنوعة.
Aveanna Healthcare (NASDAQ: AVAH) 报告了截至2025年9月27日的三个月期间的初步业绩。管理层预计 收入为6.16亿美元–6.24亿美元，同比增长约 21.0%–22.6%；净利润为1100万美元–1500万美元，同比增长约 125.7%–135.0%；以及 经调整的EBITDA为7700万美元–8100万美元，同比增长约 61.0%–69.3%。
结果为初步且未审计，需经结账程序并可能进行重大调整。公司披露了显著的非GAAP调整，包括 1570万美元–1690万美元 的与债务修改及各类并购与整合成本相关的费用。
- Revenue $616M–$624M (+21.0%–22.6% YoY)
- Net income $11M–$15M (+125.7%–135.0% YoY)
- Adjusted EBITDA $77M–$81M (+61.0%–69.3% YoY)
- Preliminary unaudited results subject to material change
- Fees related to debt modifications of $15.65M–$16.9M included in adjustments
Insights
Aveanna reports strong preliminary quarter with double‑digit revenue and large EBITDA and net‑income gains; results remain subject to final close and audit.
Aveanna shows preliminary top‑line expansion with revenue of
Key dependencies and risks remain: the results are preliminary and subject to completion of closing procedures and the independent registered public accounting firm has not reviewed or audited these numbers. The reconciliation shows sizeable adjustments, including interest expense in the range of
Watch for the finalized consolidated financial statements and the auditor review expected after the quarter ended
ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced certain preliminary financial results for the three-month period ended September 27, 2025.
For the three-month period ended September 27, 2025, we expect to report:
- Revenue of approximately
$616 million to$624 million , representing growth over the prior year third quarter of approximately21.0% to22.6% . - Net income of approximately
$11 million to$15 million , representing growth over the prior year third quarter of approximately125.7% to135.0% . - Adjusted EBITDA of approximately
$77 million to$81 million , representing growth over the prior year third quarter of approximately61.0% to69.3% .
Preliminary Financial Data
Our consolidated financial statements for our three-month period ended September 27, 2025 are not yet available. Accordingly, the financial and operational results we present in this press release are preliminary estimates and subject to the completion of our financial closing procedures and any adjustments that may result from the completion of the quarterly review and finalization of our consolidated financial statements. As a result, these preliminary estimated results may differ from actual results that will be reflected in our consolidated financial statements for the fiscal quarter when they are completed and publicly disclosed. These preliminary estimated results may change and those changes may be material.
Our expectations with respect to our unaudited results for the period discussed in this press release are based upon management estimates and are the responsibility of management. Our independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary results (including any financial data) and, accordingly, does not express an opinion or any other form of assurance with respect to these preliminary results.
Although the results of our three-month period ended September 27, 2025 are not yet finalized, the information included in this press release reflects our preliminary expectations with respect to such results based on currently available information.
Non-GAAP Financial Measures
In addition to our results of operations prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), we also evaluate our financial performance using Adjusted EBITDA. Given our determination of adjustments in arriving at our computations, these non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to net income or loss, revenue, operating income or loss, or any other financial measures calculated in accordance with GAAP.
EBITDA and Adjusted EBITDA are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with GAAP, such as net income or loss. Rather, we present EBITDA and Adjusted EBITDA as supplemental measures of our performance. We define EBITDA as net income or loss before interest expense, net; income tax expense or benefit; and depreciation and amortization. We define Adjusted EBITDA as EBITDA, adjusted for the impact of certain other items that are either non-recurring, infrequent, non-cash, unusual, or items deemed by management to not be indicative of the performance of our core operations, including impairments of goodwill, intangible assets, and other long-lived assets; non-cash, share-based compensation and associated employer payroll taxes; loss on extinguishment of debt; fees related to debt modifications; the effect of interest rate derivatives; acquisition-related and integration costs; legal costs and settlements associated with acquisition matters; restructuring costs; other legal matters; and other system transition costs, professional fees and other costs. As non-GAAP financial measures, our computations of EBITDA and Adjusted EBITDA may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of this measure impracticable.
We believe our computations of EBITDA and Adjusted EBITDA are helpful in highlighting trends in our core operating performance. In determining which adjustments are made to arrive at EBITDA and Adjusted EBITDA, we consider both (1) certain non-recurring, infrequent, non-cash or unusual items, which can vary significantly from year to year, as well as (2) certain other items that may be recurring, frequent, or settled in cash but which we do not believe are indicative of our core operating performance. We use EBITDA and Adjusted EBITDA to assess operating performance and make business decisions.
We have incurred substantial acquisition-related costs and integration costs. The underlying acquisition activities take place over a defined timeframe, have distinct project timelines and are incremental to activities and costs that arise in the ordinary course of our business. Therefore, we believe it is important to exclude these costs from our Adjusted EBITDA because it provides us a normalized view of our core, ongoing operations after integrating our acquired companies, which we believe is an important measure in assessing our performance.
The following table reconciles net income to EBITDA and Adjusted EBITDA for the period presented.
| Three-Month Period Ended September 27, 2025 | |||||||
| (dollars in thousands) | Low | High | |||||
| Net income | $ | 11,000 | $ | 15,000 | |||
| Interest expense, net | 33,600 | 34,900 | |||||
| Income tax expense (benefit) | 1,500 | (4,050 | ) | ||||
| Depreciation and amortization | 2,500 | 2,700 | |||||
| EBITDA (1) | 48,600 | 48,550 | |||||
| Goodwill, intangible and other long-lived asset impairment | 350 | 500 | |||||
| Non-cash share-based compensation | 4,700 | 5,800 | |||||
| Loss on extinguishment of debt | 5,150 | 6,600 | |||||
| Fees related to debt modifications | 15,650 | 16,900 | |||||
| Interest rate derivatives (2) | - | 50 | |||||
| Acquisition-related costs (3) | (1,000 | ) | (1,300 | ) | |||
| Integration costs (4) | 2,150 | 2,300 | |||||
| Legal costs and settlements associated with acquisition matters (5) | 1,450 | 1,600 | |||||
| Restructuring (6) | - | 100 | |||||
| Other legal matters (7) | - | 50 | |||||
| Other adjustments (8) | (50 | ) | (150 | ) | |||
| Total adjustments | 28,400 | 32,450 | |||||
| Adjusted EBITDA | $ | 77,000 | $ | 81,000 | |||
(1) EBITDA is presented in this table solely for the purposes of reconciling to Adjusted EBITDA. Values presented in the Low and High columns may not reflect the low and high ends of the EBITDA presented on account of the income tax expense (benefit) portion of the reconciliation from net income.
(2) Represents valuation adjustments and settlements associated with interest rate derivatives that are not included in interest expense, net.
(3) Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, and finance and accounting diligence and documentation.
(4) Represents (i) costs associated with our Integration Management Office, which focuses on our integration efforts and transformational projects such as systems conversions and implementations, material cost reduction and restructuring projects, among other things, of approximately
(5) Represents legal and forensic costs, as well as settlements associated with resolving legal matters arising during or as a result of our acquisition-related activities. This primarily includes (i) costs of approximately
(6) Represents costs associated with restructuring our branch and regional administrative footprint as well as our corporate overhead infrastructure costs in order to appropriately size our resources to current volumes, including: (i) branch and regional salary and severance costs; (ii) corporate salary and severance costs; and (iii) rent and lease termination costs associated with the closure of certain office locations.
(7) Represents activity related to accrued legal settlements and the related costs and expenses associated with certain judgments and arbitration awards rendered against us where certain insurance coverage is in dispute. We released a legal reserve related to a certain accrued legal settlement during the period presented.
(8) Represents: (i) other costs or (income) that are either non-cash or non-core to the our ongoing operations of approximately
About Aveanna Healthcare
Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 38 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.
Forward-Looking Statements
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and preliminary unaudited fourth quarter financial results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “would,” “predict,” “project,” “potential,” “continue,” “could,” “design,” “guidance,” or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, the risks and uncertainties set forth under the heading “Risk Factors” in Aveanna’s Annual Report on Form 10-K for its 2024 fiscal year filed with the SEC on March 13, 2025, which is available at www.sec.gov. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact Matt Buckhalter Chief Financial Officer ir@aveanna.com
FAQ
What revenue did Aveanna (AVAH) report for Q3 2025?
What was Aveanna's (AVAH) preliminary Adjusted EBITDA for Q3 2025?
How much did Aveanna (AVAH) report in preliminary net income for Q3 2025?
Are Aveanna's Q3 2025 results final for AVAH?
What non-GAAP adjustments did Aveanna (AVAH) disclose for Q3 2025?
Will Aveanna's (AVAH) independent auditor review the preliminary Q3 2025 numbers?
